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Stimuli for arginine vasopressin release mclude byperocmo. 
larity mediated by receptors in the hypothalamus and intra- 
vascular volume depletion mediated by mechanoreceptorr 
located within the pulmonary veins. atria. left ventricle and 
carotid sinus and along the aorta (l-3). Although atrial and 
otlwlow pressure receptors appear to play the major role in 
the nonosmotic regulation of vasopressin release in dogs 
(4,5), recent w-k (6-P) has cast doubt on the role of such 
receptors in primates and humans and has instead supported 
primary involvement ofhigh pressure Gnaaortic and ventric- 
ular receptors. 
Evidence for exapgerated artinine vasopressin release in 
the fetus and neon&has beenberoonstra~ed in animal and 
human studies Wl-16). There is also evidence from fetal 
studies (l2,13,17-IV) to suggest tbat the c~cutatory effects of 
vasopressin may be augmented in the neonate as compared 
with the adult. Therefore, vasopressin may be an imponant 
component of cardiovascular control in early life. 
Certzis form5 of congelliiai iwart disease cdusing were 
congestive heart failure m neonates have as thcs common 
denommamr left ventricular outflow tract obstruction in 
which the aorta nd left ventwle are small and there is also 
severe pulmonary venous and left atrial hypertension. Be- 
cause arginme vasopresoin may play a prominent role in 
vascular egulation in neonates. the amt of this investigation 
was to as&n plasma levels of arginine vasopres& in 
stressed infats with heart failure associated with the pre+ 
ewe or abcence of lefl ventricular outflow tract ohdructioo. 
Methods 
Study patients. Twenty-ceven patients were enrolled m 
this stud” after informed consent WB$ obtained accordinr: to
a protocol approved by the Human Subjects Administrarion 
at our inrtitution. All patients were full-term infan!s and 
were free from noncardiac disease. Patients recewed a code 
nwnbrr devrloped d!~dqS pwrewing of :nmp!es in nrrl~r to 
blind vasoprcssin assays from clinical data. and were as- 
signed to one of three diagnostic groups. 
Grwp I icongeaiw hem fuilrrrr with lefr vewkslor 
ou~fh mcr obsmrcrhn) consisted of nine fuil-term infants 
aged I to 1 days tmean 4 2 I) with left ventricular outflow 
tract obstruction and acute heart &lure characterized by 
tachypnea. tacnycardia. hepatomegaly and nbsence of pri- 
mary polmonary disease. Left ventriculm mass and aortic 
size were decreased in every patient. Specific diagnoses are 
shown in Table I, All nine infants in Group I eventually 
received iniusions of dopamine (5 to 12.5 @kg body weight 
per mini, prostaglandin El (0.05 I” n I5 &kg per min) and 
furosemide (I to 2 mgikg per dose), although at the time of 
inilial presentation only fourofthe nine had been given these 
medications (Table I). Positive pressure ventilsrion was 
employed in three of the nine infants. ad arterial ines were 
erlablished in all. Improvement in hem failure status, as 
measured by normalization of blood pressure and acid-base 
balance and by rraintenancc of good peripheral perfusion 
and urinary output. was observed in er’ery infant before any 
surgical intervention. 
Cwtp I! (caagesrive :~arrJXxm !!+hoar lefl vrnrricular 
sG4i;? iitiic! ubsfnrtiionJ consisted of trtht tull-term infants 
aged 1 fo 24 days (mean 15 + 7) who pkmed with acute 
heart failure as described, but who were free of left ventric- 
ular outflow tract obstruction (see Table I for specific 
diagnoses). Five of the eight infants eventually received 
digoxin. all evenlually received furosemide and three of 
eight e~cnt~ally received dopamine. Positive pressure ven- 
tilation was employed in two of the eight. None of the eight 
received pmstaglandin E, and, at the time of initial presen- 
tation. only two of the cigltl had been given digoxin and 
furosemide. Arterial lines were established in all infants 
receiving dopaminc. 
Group III (control) infants consisted of 10 heahhy, un- 
stressed full-term neonates aged 2 to I I days (mean 4 + 2,. 
Clinical procedures. Infants in Groups I and II had deter- 
minations of serum electrolytes, blood count and blcai 
gases and therapeutic interventions performed for mutine 
clinical indications. A chest radioeraoh. an elrwacardio- 
grtmt (ECG) and a two-ditnensi&l &wdiogram were 
obtained at least once for each infant in these groups. Infants 
with anatomic heart disease had their diagnosis confirmed by 
cardiac catheterization, with the exception ai those with 
hypoplastic left heart synd-ome, whose diagnosis WB estab 
lished by echocerdiogetphy. Vital signs art physical exam- 
ination findings were used as part of the as~esstnent of 
clinical course. Clinical data at the time of presentation in 
infants with heart failure au: shown in Table.1. Medications 
being given at the time oimitial evaluation and vasopressin 
assay are noted. 
Arghtine vasopressin way. Blood samples of < I ml, hut 
providing at least 0.3 ml of serum, were taken for vasoprer- 
sin assay. Specimens from infants in Group III were ob- 
tained on only one occasion, at the time of phenylketonuria 
assay. Blood sampling was preferentially petfotmed through 
indwelling catheters when present. In ill infants. first sent- 
pies were collected as close as possible to the time of 
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Figure 2. Serum arginine vasopressin concentrations (AVP cone.)
in picograms per milliliter for five infants withcongestive heart
failure andleftventricular outflow tractobstruction whohadinitial
vasopressin levels assessed before medical therapy (Group IA)as
compared withvalues in four infants withleftventricular outflow
tractobstruction whohad initial vasopressin levels assessed after
therapy (Group 18). Arginine vasopressin concentrations before
(PreRx) andafter(postRx) therapy for Group fA are alsoshown.
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Figure 1. Serum arginine vasopressin concentrations (AVP conc.)
inpicograms permilliliter forall27infants inthethreestudygroups.
The mean values and standard errorof the mean (SEM) of vaso-
pressin foreachofthepatient groups areplotted ona broken linear
scalefor serum concentration. CHF = congestive heart failure;
LVOTO = left ventricular outflow tract obstruction. The three
columns represent Groups I, II andIII, respectively.
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recognition of illness and on a daily basis thereafter. For
purposes of statistical analysis of Groups I and II, plasma
argininevasopressin levelsobtainedfromfirst bloodsamples
were used for data analysis.
Each blood specimen was placed in a sterile tube con-
taining 10J.dof heparin (1000IU/ml)and refrigerated imme-
diately. Within 3 hours, the tube was briefly spun in a high
speed centrifuge and the serum was withdrawn and trans-
ferred to a second test tube containing0.5 ml of IN hydro-
chloricacid. The acidifiedserum was frozen, pendingvaso-
pressin extraction. Extraction was effectedby the Bentonite
technique described by Skowskyet al. (20)and modifiedin
our laboratory by treatment with petroleum ether and lyo-
philization of the eluate (Speed-Vee, Savant Instrument
Inc.). Radioimmunoassay was performed according to an
established technique using serum arginine vasopressin an-
tibody (21). Intraassay variabilityhas been 4% and interas-
say variability has been 10%. Percent recovery has been
measured with each previous assay performed, and consis-
tently ranged between 80and 85%.
Statistical analysis. Data were not normally distributed.
Therefore, statistical comparisonswere performed usingthe
Wilcoxon-Mann-Whitney test for nonparametric consider-
ation of two-tailed two sample testing (22). Significance
required p values <0.05.
Results
Individual patient data are presented in Table 1, and
averagedgroup data are shown in Figures I through 3.Table
I lists vital signs (heart rate, respiratory rate and blood
pressure), serum sodium levels, arterial pH, assisted venti-
lation status and medications being received at the time of
initial samplingfor argininevasopressin.
Plasma vasopressin concentrations (Fig. 1). In newborn
infants with congestiveheart failure, the argininevasopres-
sin levels were significantly different(p < 0.001),depending
on the presence or absence of left ventricular outflowtract
obstruction. Neonates with heart failure without left ventri-
cular outflowtract obstruction (Group II) had a significantly
higher mean plasma arginine vasopressin concentration (80
± 18pg!ml) than did control infants (6.0 ± 0.7 pg!ml, p <
0.001). Neonates with heart failure with left ventricular
outflowtract obstruction (Group I) had a significantly lower
mean plasma argininevasopressin concentration (3.0 ± 0.7
pg!ml) than did control infants (p < 0.05).
Role of medicaltherapy (Fig. 2 and 3). Five of the nine
Group I infants had arginine vasopressin levels measured
before initiationof any medical therapy. Figure 2 compares
results for infants in Group I who did not receive medical
therapy before the initial vasopressin measurement (Group
lA, 3.6 ± 1.0pglml)with results for infants who did receive
medical therapy before initial vasopressin measurement
(Group IB, 2.6 ± 0.4 pg/ml). Also, vasopressin levels for
infants in Group IA obtained after initiation of medical
therapy (3.8 ± 1.3 pglml)are compared with levels in these
same patients before medical therapy. No statistically sig-
nificant changes in arginine vasopressin plasma concentra-
tion were noted after the initiationof dopamine, furosemide
and prostaglandin E, therapy or with positive pressure
ventilation in these patients.
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Figure 3. Serumarginine vasopressin concentrations (AVPconc.)
in picograms per milliliter for five infants with congestive heart
failureand left ventricularoutflow tract obstruction who hadinitial
vasopressin levelsassessed beforemedical therapy(GroupfA)as
comparedwith values in six infantswith congestive heart failure
withoutleft ventricularoutflow tract obstruction who had initial
vasopressin levelsassessedbeforemedicaltherapy(GroupHAl.
Six of the eight infants in GroupII had arginine vaso-
pressinlevelsassessedbeforethe initiation of medical ther-
apy. Figure 3 compares results for infants in Group I with
leftventricular outflow tractobstruction whodidnotreceive
medical therapybeforethe initial vasopressin measurement
(Group IA) with those for infantsin GroupII withoutleft
ventricular outflow tract obstruction who also did not re-
ceive therapy before initial vasopressin measurement
(GroupIIA). Infantsin GroupIA had a significantly (p <
0.01) lower vasopressin level (3.6 ± 1.0 pg/ml) than did
infantsin GroupIIA (90 ± 23pg/ml).
Discussion
Our results indicate that plasmaconcentrations of argi-
nine vasopressin in neonateswith acute congestive heart
failure are affected by the specific etiology of the heart
failure. In the presence of left ventricular outflow tract
obstruction, vasopressin levelsare low. In the absenceof
leftventricular outflow tract obstruction, vasopressin levels
are markedly increased.
Roleof arginine vasopressin in congestive heart failure.
Increased vasopressin levels in neonates with congestive
heart failure in the absenceof left ventricular outflow tract
obstruction (GroupII) are consistent withreported results
foundinadults, and may be explained in the contextof the
currentunderstanding of the roleof arginine vasopressin in
heart failure. Patients with heart failure frequently have
increased systemic vascular resistance, which may be
viewed as an adaptivemechanism to lowcardiacoutput in
congestive heart failureor as a sustaining component of the
congestive state. Suchan elevatedvascularresistance may
resultfromincreased sympathetic nervoussystemstimula-
tion and increased activityof the renin-angiotensin system
(23,24). Arginine vasopressin hasalsobeendemonstrated to
be increased inadultswithcongestive heartfailure and may
playa vasoconstrictive and antidiuretic role, but the exact
extentof vasopressin involvement in heartfailure is contro-
versial (25-34). Recent investigations (35) in adults with
congestive heart failuregiven exogenous hormone suggest
thatvasopressin exertssignificant adversecirculatory effects
at concentrations comparable withthosemeasured inGroup
II neonatesin the presentstudy.
Roleof highpressure sinoaortic and ventricular receptors
in the release of vasopressin. Patients in GroupII with the
highest levels of vasopressin were those presenting with
hypotension. This is in accord with current observations
(7,34,36) on the importance of the highpressuresinoaortic
and ventricular receptors for the release of vasopressin.
Thus,as inadultswithheartfailure,children inourGroupII
with acute heart failure have increased plasma levels of
arginine vasopressin, and those with hypotension have the
highest levels recorded. Increasedvasopressin under such
conditions mayconstitute an adaptiveresponse to lowblood
pressureby the direct vasoconstrictive actionsof the hor-
mone and by its interaction with the baroreceptors and
central nervous system (36-42). As in some adults, such
markedly elevated arginine vasopressin levels might ad-
versely affect afterload in the presenceof a failing heart
(30,31).
Contribution ofvasopressin to blood pressure maintenance
inearlylife. Sympathetic nervoussystem-vasopressin inter-
action is thoughtto blunt the vasoconstrictive responsein
adult animals and humans administered exogenous vaso-
pressin(26-28). However, fetal lambs(18)or autonomically
impaired adult animals and humans(39,41) given arginine
vasopressin maintain a pressorresponse.In sympathetically
denervated animals, arginine vasopressin is an important
defenseagainst hypotension. There is evidence (37.43,44)
that, as compared with adults, neonates have impaired
autonomic capacity, particularly involving the sympathetic
nervous system. Also, neonates may have an enhanced
ability to release vasopressin in amounts far in excess of
thoseusually associated withantidiuresis (12-15,45). There-
fore, neonates may depend more heavily than adults on
hormonal mechanisms for bloodpressurecontrol,and this
may partially account for the higherarginine vasopressin
levelsmeasured in GroupII neonateswithheart failure as
compared withthose in adultswithheart failure.
Importance of high pressure receptors for vasopressin
release in congestive heart failure. The principal finding in
thisstudyisthat infantswithcongestive heartfailure andleft
ventricular outflow tract obstruction (Group I), who are
almostuniformly hypotensive at clinical presentation, have
plasmalevelsofarginine vasopressin inappropriately lowfor
their clinical circumstances. One possible cause of this
condition is the hypoplasia of the aorta and left ventricle
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Figure 4. Course ofthecirculation, percent oxygen saturations (in
circles) and pressures (mm Hg) in the hypoplastic leftheart syn-
drome (mitral andaortic [Ao] atresia). DA == descending aorta; IVC
= inferior vena cava; LA == leftatrium; LV"" leftventricle; m =
mean; PA= pulmonary artery; PV= pulmonary vein; RA = right
atrium; RV = right ventricle; SVC == superior vena cava. (Reprinted
from Rudolph AM. Congenital Diseases oftheHeart. Chicago: Year
Book Medical, 1974:554, with permission.)
seenin thisgroupof leftventricularoutflow tract obstruction
lesions. Figure 4 illustrates the anatomic and physiologic
disturbances in left ventricularoutflow tract obstruction as
exemplified by the hypoplastic left heart syndrome.Blood
flow is diverted away from the sinoaortic area and left
ventricle, resulting in developmental hypoplasia of these
structures. Alterationsin highpressure receptors could be
expectedto accompany such hypoplasia and thus alter the
responsiveness to the nonosmotic stimuli for vasopressin
release.
Arginine vasopressin plasmalevelsmeasuredin control
infants(Group Ill) werecomparable withlevelsreportedfor
newborn infants (12-15,45) and were generally higherthan
levelsreportedfor normaladults.This discrepancy maybe
accountedfor byage-related changesinarginine vasopressin
levelsthat occurin the perinatalperiod.Levelsare highest in
umbilical cord blood, and rapidly decrease to near adult
levelswithinseveral days (45). It is unlikely that such age
dependence could affect the statistical significance of our
results.Infantsin GroupI (withleftventricularoutflow tract
obstruction) constituted the youngest group at the time of
enrollment in the study. Theirearly postnatalage mightbe
expectedto beassociatedwithincreasedvasopressin levels.
Instead, these infantshad the lowest levelsmeasured. In-
fants in Group II (without left ventricular outflow tract
obstruction) constituted the oldest group at the time of
enrollment in the study. Their older postnatalage mightbe
expectedto beassociatedwithdecreasedvasopressin levels
as comparedwiththosein controlinfants.Instead, infantsin
GroupII hadmarkedly elevatedlevels.Although onlyfiveof
the nine infantsin Group I had vasopressin levelsobtained
before initiation of specific medical therapy, such therapy
did not appear to be related to the levels measured this
group.
Osmotic factors did not appearto playa majorrole in
determining vasopressin concentration. In all patients, se-
rum sodium and calculated osmolarity were within the
normalrangethroughout the course of the illness.
Conclusions. In newborn infants, significant increasesin
plasmaarginine vasopressin levelsover control levelswere
associatedwithcongestive heart failureinthe absenceofleft
ventricularoutflow obstruction, whilesignificant decreases
in vasopressin were associated with heart failure in the
presence of left ventricular outflow tract obstruction. In
infants with left ventricularoutflowtract obstruction, de-
creasedvasopressin levelsmayserveto aggravate the severe
hypotension characteristic of such lesions, which is an
undesirable effectfor circulatoryhomeostasis. These data
supportthe hypothesis that the nonosmotic releaseof argi-
nine vasopressin is related to the integrity of the high
pressuresinoaortic and leftventricularreceptors.Vasopres-
sin levels are increasedwhen high pressure receptors are
intact, but forward flow is diminished, as in heart failure
without left ventricular outflow obstruction. Vasopressin
levelsare decreasedwhenhighpressurereceptoractivityis
impaired, as in heart failure with left ventricularoutflow
tract obstructioncaused by poorlydeveloped cardiacanat-
omy.
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